3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Lung Neoplasms
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Interventions
pembrolizumab
59
Carboplatin
56
Pemetrexed
47
Cisplatin
39
Paclitaxel
24
Nivolumab
23
Docetaxel
21
durvalumab
20
Gemcitabine
15
130-nm albumin-bound paclitaxel
14
osimertinib
13
Cetuximab
12
Specimen Handling
11
Magnetic Resonance Spectroscopy
11
atezolizumab
10
amivantamab
8
Taxes
8
Radiotherapy
8
Radiosurgery
7
Ipilimumab
7
lazertinib
6
alectinib
6
Ramucirumab
6
Observation
6
Bevacizumab
6
cemiplimab
5
Leucovorin
5
Fluorouracil
5
Etoposide
5
Erlotinib Hydrochloride
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
monalizumab
×
30 days
×
Clear all
NCT05061550
2026-05-22
NeoCOAST-2
AstraZeneca
Phase 2
Recruiting
630 enrolled
NCT05221840
2026-05-18
PACIFIC-9
AstraZeneca
Phase 3
Active not recruiting
1,051 enrolled